Equillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker of Disease Severity in Lupus Nephritis at ACR Convergence 2022Business Wire • 11/14/22
Equillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia AreataBusiness Wire • 11/10/22
Equillium Announces Presentation at the 6th Annual Dermatology Drug Development SummitBusiness Wire • 11/03/22
Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac DiseaseBusiness Wire • 11/02/22
Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology ConferenceBusiness Wire • 10/26/22
METACRINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Metacrine Inc. - MTCRBusiness Wire • 10/04/22
Equillium's stock is up 12% after sharing early data about its investigational lupus treatmentMarket Watch • 09/27/22
Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus NephritisBusiness Wire • 09/27/22
Equillium Announces Abstract Accepted for Presentation at ACR Convergence 2022Business Wire • 09/15/22
EQ Stock Alert: Halper Sadeh LLP is Investigating Whether the Merger of Equillium, Inc. is Fair to ShareholdersBusiness Wire • 09/06/22
Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development UpdatesBusiness Wire • 08/15/22
Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development SummitBusiness Wire • 07/28/22
Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development UpdatesBusiness Wire • 05/12/22
Equillium Announces Publication of Abstract for the Annual Congress of the European Hematology AssociationBusiness Wire • 05/12/22
Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of ImmunologistsBusiness Wire • 05/09/22
Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTRBusiness Wire • 04/25/22
Equillium Announces Oral Presentation at the Italian Society of Experimental HematologyBusiness Wire • 04/04/22
Down 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Equillium, Inc. (EQ)Zacks Investment Research • 03/29/22
Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development UpdatesBusiness Wire • 03/23/22